Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / PPBP



This biomarker is also known as:
  • small inducible cytokine B7,
  • pro-platelet basic protein,
  • Beta-TG,
  • NAP-2-L1,
  • platelet basic protein,
  • TGB,
  • CTAP3,
  • connective tissue-activating peptide III,
  • neutrophil-activating peptide 2,
  • TGB1,
  • thrombocidin 2,
  • thrombocidin 1,
  • THBGB1,
  • LDGF,
  • NAP-2,
  • macrophage-derived growth factor,
  • thromboglobulin, beta-1,
  • TC1,
  • pro-platelet basic protein (chemokine (C-X-C motif) ligand 7),
  • THBGB,
  • TC2,
  • small inducible cytokine subfamily B, member 7,
  • CXCL7,
  • leukocyte-derived growth factor,
  • B-TG1,
  • LA-PF4,
  • CXC chemokine ligand 7,
  • PBP,
  • neutrophil-activating peptide-2,
  • low-affinity platelet factor IV,
  • beta-thromboglobulin,
  • b-TG1,
  • SCYB7,
  • MDGF,

View in BioMuta


CTAP-III (officially named PPBP) is a platelet-derived growth factor that belongs to the CXC chemokine family. This growth factor is a potent chemoattractant and activator of neutrophils. It has been shown to stimulate various cellular processes including DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and sythesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by synovial cells.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Three
QA State: Curated


CTAP-III was identified to be significantly higher in venous than in arterial blood. CTAP III levels decreased after lung tumor resection (P = .01). In two independent population cohorts, CTAP III was significantly associated with lung cancer. CTAP-III may also modify breast cancer cells and surrounding extracellular matrix to facilitate metastasis. In contrast to earlier findings from analyzes of postdiagnostically collected sera, the addition of 7 biomarkers (apolipoprotein A1 (APOA1), truncated transthyretin (TTR), transferrin (TF), hepcidin (HAMP), β-2 microglobulin B2M), connective tissue activating protein III (CTAPIII, a.k.a PPBP) to CA 125 did not improve sensitivity for preclinical diagnosis of ovarian cancer beyond CA 125 alone.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. CTAP-III, also known as PPBP, alone was not a strong predictor.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.